I’m thinking it is.

Just look at the headlines:

After Successful ALS Phase I, Neuralstem Branches Out  ($CUR)

Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center ($CUR)

Rejuvenated Regenerative Medicine: Stem Cells and Athersys on the Rise ($ATHX)

Athersys’ MultiStem Platform Tempts Big Pharma And Investors ($ATHX)

Meanwhile, $ATHX daily chart shows a cup & handle pattern with one giant handle:

Is this a good sign with a big handle?  Beat me!  Nevertheless, the chart does look like it has a lot of support in the $1.50 area going back to last year.

$CUR daily chart, on the other hand, is showing a come-back V shape pattern:

I like to see price action breakout of the downtrend line at the $1.20 area to show that it means business.

Either way, I’m betting my 2 cents that 2013 may be a good year for Stem Cells.  And I’m rooting for $CUR to have a successful ALS phase II trial.  It will be a milestone for those who suffers from the disease.

I currently own both $CUR and $ATHX.

My 2 cents.

Comments »